hotspot -WSS

hotspot

author：Wikipedia 2025-09-29 01:06:59 - browse：79655

Person wearing a smart watch. -- first opinion coverage from STAT — Adobe

The Apple Watch has secured a new qualification from the Food and Drug Administration that could make the smartwatch an appealing tool for medical device companies hoping to illustrate the benefits of a common heart procedure.

Last week, the Apple Watch’s Atrial Fibrillation History feature became the first digital tool qualified under the Medical Device Development Tools (MDDT) program. Released in 2022, the feature estimates a user’s A-fib burden, or how much time they spend in atrial fibrillation, which is an irregular heart rhythm that can cause shortness of breath and fatigue, and is also linked to an increased risk of stroke.

The qualification means that FDA has determined in advance that sponsors can use the feature as a secondary endpoint in clinical trials without having to do additional work. Specifically, the Apple Watch is qualified for use as a secondary endpoint in clinical trials for cardiac ablation devices, which reduce the electrical signals that cause A-fib by scarring the heart with extreme heat or cold energy. Pulsed field ablation is the latest version of the technology, using a controlled electric field to scar tissue rather than the riskier thermal energy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： CDC says it’s too soon to assess risk posed by Covid subvariant

focus

WSS

Republicans love RFK Jr. What's that tell us about health in 2024?

People can get long Covid without testing positive for virus: Study

Republicans love RFK Jr. What's that tell us about health in 2024?

Midwives could help bridge maternal health disparities in the U.S.

As obesity drug market grows, telehealth companies court payers

Why the quest to eradicate polio has stumbled

knowledge

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Wikipedia

How one medical school became remarkably diverse

Covid’s new normal has set in amid another rise in cases

At least 13 dead in Texas as scorching temps continue

David Liu startup to focus on CRISPR delivery

Bright Health sells Medicare Advantage business to Molina

Can U.S. cancer drug shortages be fixed?

Medicare details structure of new drug price negotiation program

Roche's accidental data boosts hopes for anti

Wildfire smoke exposes gaps in outdoor worker protections

CDC says it’s too soon to assess risk posed by Covid subvariant

focus

FDA advisory panel to debate high blood pressure devices

The struggle to figure out which patients 'deserve' Wegovy

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Neurocrine congenital adrenal hyperplasia trial succeeds

Can U.S. cancer drug shortages be fixed?

Can U.S. cancer drug shortages be fixed?

explore

focus

hotspot

hotspot